Premium
Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti‐MicroRNA Therapies
Author(s) -
Beavers Kelsey R.,
Werfel Thomas A.,
Shen Tianwei,
Kavanaugh Taylor E.,
Kilchrist Kameron V.,
Mares Jeremy W.,
Fain Joshua S.,
Wiese Carrie B.,
Vickers Kasey C.,
Weiss Sharon M.,
Duvall Craig L.
Publication year - 2016
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201601646
Subject(s) - materials science , porous silicon , nucleic acid , peptide nucleic acid , nanotechnology , in vivo , endosome , polymer , drug delivery , peptide , intracellular , microrna , silicon , conjugated system , nanoparticle , nanocomposite , combinatorial chemistry , biophysics , chemistry , biochemistry , gene , biology , composite material , microbiology and biotechnology , metallurgy
Self‐assembled polymer/porous silicon nanocomposites overcome intracellular and systemic barriers for in vivo application of peptide nucleic acid (PNA) anti‐microRNA therapeutics. Porous silicon (PSi) is leveraged as a biodegradable scaffold with high drug‐cargo‐loading capacity. Functionalization with a diblock polymer improves PSi nanoparticle colloidal stability, in vivo pharmacokinetics, and intracellular bioavailability through endosomal escape, enabling PNA to inhibit miR‐122 in vivo.